Biomerica (BMRA) Income from Continuing Operations (2010 - 2026)
Biomerica (BMRA) reported Income from Continuing Operations of 1312000.0 for Q1 2026, down 12.81% on a YoY basis from 1504788.95 in Q1 2025, and up 0.61% sequentially from 1320000.0 in Q4 2025.
Biomerica (BMRA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Biomerica (BMRA) has 17 years of Income from Continuing Operations data on file, last reported at 1312000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 12.81% year-over-year to 1312000.0; the trailing twelve-month figure through Feb 2026 stood at 4172000.0 (up 10.47% YoY), and the FY2025 full-year result was 4971000.0, up 14.12% from the prior year.
- Income from Continuing Operations grew to 1312000.0 in Q1 2026, from 1320000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2000.0 in Q3 2025 to a low of 2324000.0 in Q2 2023.
- A 5-year average of 1348479.12 and a median of 1320000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 1483.98% in 2023 and jumped 100.15% in 2025, its largest moves.
- Tracing BMRA's Income from Continuing Operations over 5 years: stood at 1626000.0 in 2022, then rose by 7.32% to 1507000.0 in 2023, then jumped by 36.96% to 950000.0 in 2024, then sank by 38.95% to 1320000.0 in 2025, then increased by 0.61% to 1312000.0 in 2026.
- Business Quant data shows BMRA's Income from Continuing Operations at 1312000.0 in Q1 2026, 1320000.0 in Q4 2025, and 2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Biomerica | 4.85 Mn | 3.51 Mn | -44,000.00 | -1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -1.31 Mn |
| Nov 30, 2025 | -1.32 Mn |
| Aug 31, 2025 | 2,000.00 |
| May 31, 2025 | -1.54 Mn |
| Feb 28, 2025 | -1.16 Mn |
| Nov 30, 2024 | -950,000.00 |
| Aug 31, 2024 | -1.32 Mn |
| May 31, 2024 | -1.23 Mn |
| Feb 29, 2024 | -1.92 Mn |
| Nov 30, 2023 | -1.51 Mn |
| Aug 31, 2023 | -1.13 Mn |
| May 31, 2023 | -2.32 Mn |
| Feb 28, 2023 | -1.65 Mn |
| Nov 30, 2022 | -1.63 Mn |
| Aug 31, 2022 | -2.07 Mn |
| May 31, 2022 | -1.76 Mn |
| Feb 28, 2022 | -104,168.00 |
| Nov 30, 2021 | -1.13 Mn |
| Aug 31, 2021 | -1.54 Mn |
| May 31, 2021 | -3.26 Mn |